Short-term reductioidin bone markers with high-dose simvastatin

Osteoporosis International

Volumn 16, Issue 10, 2005, Pages 1272-1276

  Rosenson, Robert S ^a   Tangney, Christine C ^b   Langman, Craig B ^c   Parker, Thomas S ^d   Levine, Daniel M ^d   Gordon, Bruce R ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d ROGOSIN INSTITUTE   (United States)

Author keywords

Bone density; Bone markers; Cholesterol lowering therapies; Osteoporosis; Statins

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OSTEOCALCIN; PLACEBO; PLASMA PROTEIN; PRAVASTATIN; SIMVASTATIN; COLLAGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; URINARY N TELOPEPTIDE OF TYPE I COLLAGEN, HUMAN; URINARY N-TELOPEPTIDE OF TYPE I COLLAGEN, HUMAN;

ADULT; ARTICLE; BLOOD SAMPLING; BODY MASS; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG SAFETY; DRUG USE; ENZYME SPECIFICITY; FEMALE; HUMAN; INFECTION; MALE; MYOSITIS; NORMAL HUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SMOKING; BLOOD; BONE REMODELING; DOSE RESPONSE; DRUG EFFECT; HYPERCHOLESTEROLEMIA; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; URINE;

ADULT; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; BONE REMODELING; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPIDS; MALE; MIDDLE AGED; OSTEOCALCIN; PRAVASTATIN; SIMVASTATIN;

EID: 25844456644     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1897-1     Document Type: Article

References (15)

1. Mundy G, Garrett R, Harris S et al (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
2. Staal A, Frith JC, French MH et al (2003) The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18:88-96
3. Bauer DC, Mundy GR, Jamal SA et al (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146-152
4. Stein EA, Farnier M, Waldstreicher J, Mercuri M (2001) Effects of statins on biomarkers of bone metabolism: a randomised trial. Nutr Metab Cardiovasc Dis 11:84-87
5. Rejnmark L, Buus NH, Vestergaard P, Andreasen F, Larsen ML, Mosekilde L (2002) Statins decrease bone turnover in postmenopausal women: a cross-sectional study. Eur J Clin Invest 32:581-589
6. Balica M, Bostrom K, Shin V, Tillisch K, Demer LL (1997) Calcifying subpopulation of bovine aortic smooth muscle cells is responsive to 17 beta-estradiol. Circulation 95:1954-1960
7. The Heart Protection Study Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7-22
8. Edwards CJ, Hart DJ, Spector TD (2000) Oral statins and increased bone-mineral density in postmenopausal women. Lancet 355:2218-2219
9. LaCroix AZ, Cauley JA, Pettinger M et al (2003) Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study. Ann Intern Med 139:97-104
10. Rejnmark L, Buus NH, Vestergaard P et al (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737-744
11. (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1-45
12. Otvos JD (2002) Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48:171-180
13. The Scandinavian Simvastatin Survival Study Group. (1994) Randomised trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344:1383-1389
14. Reid IR, Hague W, Emberson J et al (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509-512
15. Pasternak RC, Smith SC Jr, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 40:567-572